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Insights into the role of sulfated 
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The tetra-branched peptide NT4 selectively binds to different human cancer cells and tissues. 
NT4 specifically binds to sulfated glycosaminoglycans on cancer cell membranes. Since sulfated 
glycosaminoglycans are involved in cancer cell interaction with the extracellular matrix, we evaluated 
the effect of NT4 on cancer cell adhesion and migration. We demonstrated here that the branched 
peptide NT4 binds sulfated glycosaminoglycans with high affinity and with preferential binding 
to heparan sulfate. NT4 inhibits cancer cell adhesion and migration on different proteins, without 
modifying cancer cell morphology or their ability to produce protrusions, but dramatically affecting 
the directionality and polarity of cell movement. Results obtained by taking advantage of the selective 
targeting of glycosaminoglycans chains by NT4, provide insights into the role of heparan sulfate 
proteoglycans in cancer cell adhesion and migration and suggest a determinant role of sulfated 
glycosaminoglycans in the control of cancer cell directional migration.
In previous papers we reported the synthesis and biological activity of stable tetra-branched peptides containing 
the sequence of human neurotensin (NT4), coupled with different tracers or chemotherapy drugs. NT4 peptides 
bind with high selectivity to cells and tissues from human cancers, such as colorectal cancer, pancreas adenocar-
cinoma and urinary bladder cancer, and can efficiently and selectively deliver drugs or liposomes for cancer cell 
imaging or therapy. By conjugating NT4 with methotrexate or 5FdU, we obtained significantly higher reduction 
of tumor growth in mice than in mice treated with the same amount of unconjugated drug. More recently, we 
found that conjugation of paclitaxel to NT4 led to increased therapeutic activity of the drug in an orthotopic 
model of breast cancer in mice and produced tumor regression which was not achieved with unconjugated pacl-
itaxel in identical experimental conditions1–6. NT4 branched peptides were therefore proposed as promising 
selective cancer theranostics.
We found that the much higher binding of NT4 peptides than native neurotensin to cancer cell lines and 
human cancer surgical samples was generated by a switch in selectivity towards additional membrane receptors, 
which are selectively expressed by different human cancers. We demonstrated that the branched structure enables 
NT4 to bind membrane sulfated glycosaminoglycans (GAG), as well as different membrane endocytic receptors 
belonging to the low density lipoprotein receptor related (LRP) protein family such as LRP1 and LRP6, which are 
already known to be potentially druggable tumor markers involved in cancer biology7. Systematic modification 
of the neurotensin sequence in the NT4 peptide led to identification of a multimeric positively-charged motif 
that mediates interaction with heparin and endocytic receptors. The motif is very similar to heparin-binding 
motives contained in midkine and other proteins, like Wnt, which bind sulfated glycans and LRP receptors and 
are over-expressed in cancer7.
GAGs are large, linear, negatively charged polysaccharides consisting of repeating disaccharide units that can 
be sulfated at different positions and to different extents. Five glycosaminoglycan chains have been identified: 
heparan sulfate (HS), chondroitin sulfate (CS), dermatan sulfate (DS), and keratan sulfate and the non-sulfated 
hyaluronic acid8.
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Sulfated GAG chains are linked covalently to core proteins, generating proteoglycans. Depending on the core 
protein, these can be divided into transmembrane (syndecan), GPI-anchored (glypican), and secreted (perlecan) 
heparan sulfate proteoglycans (HSPG)9–11.
The biological functions of HSPG reside in their ability to interact with various ligands, and this is strictly 
related to the extent to which sulfated groups of their GAG chains can be modulated. Chain structure and espe-
cially the amount and position of sulfated groups in GAGs are essential for HSPG specificity and affinity toward 
different ligands12,13.
Sulfated GAGs modulate cell differentiation as well as cell–cell and cell–ECM interactions by binding to sev-
eral bioactive molecules, including chemokines, cytokines, growth factors, morphogens, adhesion molecules and 
matrix components, such as collagen, fibronectin, laminin and vitronectin14–16.
As a consequence of their specific binding to several growth factors and morphogens, sulfated GAGs are able 
to regulate cell differentiation and are involved in epithelial mesenchymal transition and carcinogenesis9,11,17. 
Moreover, by binding to heparin-binding sites of ECM components, sulfated GAGs collaborate with integrins 
for cell-ECM interactions in cell adhesion and migration18,19. Sulfated GAGs are therefore essential regulators of 
cancer progression through modulation of cell differentiation, invasion and metastasis.
Compared with non-neoplastic ECM, tumor associated ECM contains higher concentrations of various 
growth factors and large amounts of specific proteoglycans and GAGs8,10. Cancer cell membranes and tumor 
associated ECM are also characterized by a predominant presence of highly sulfated GAGs, which have already 
been identified as tumor markers in cancers such as hepatocellular carcinoma (where glypican 3 is a clinically 
experimented marker)20, breast cancer21, ovarian cancer22,23, colorectal cancer24, and others25. Moreover, enzymes 
regulating membrane shedding of HSPG as well as sulfatases, which regulate the number of sulfated groups on 
the GAG chain, are known to have a determinant role in cancer development and invasiveness26–28. Nonetheless, 
the molecular basis of the biological function of sulfated GAGs is still poorly defined, mainly due to the lack of 
specific HSPG ligands that could enable the role of the glycan chains to be discriminated from that of the core 
protein.
Endocytic receptors, like LRP1, LRP6 and sortilin, are known to bind heparin-binding ligands, such as Wnt, 
sclerostin, ApoE and midkine, by means of electrostatic interactions between spots of negatively and positively 
charged residues on receptors and ligands, respectively29,30. LRP receptors and sortilin are both known to play a 
role in cell adhesion, migration and differentiation31–35, though as in the case of HSPG, the molecular mechanism 
underlying their complex functions is far from clear.
Since NT4 branched peptides can specifically interact with sulfated GAGs and heparin-mimicking endocytic 
receptors, here we analyzed the effect of the tetra-branched NT4 peptide on cancer cell adhesion and motility on 
different supports. NT4 inhibited adhesion of PANC-1 human pancreas adenocarcinoma cells to plastic, collagen 
IV and oncofetal human cellular fibronectin, whereas it did not affect cell adhesion to soluble plasma fibronectin. 
NT4 also inhibited cancer cell migration on different supports, dramatically affecting its directionality. These 
results suggest that besides their possible use as selective cancer theranostics, NT4 peptides may interfere with 
cancer cell migration and adhesion, thus reducing tumor aggressiveness and metastatic potential. These results 
also provide insights into the role of HSPG and LRP receptors in cancer cell adhesion and motility on different 
ECM proteins.
Results
The tetra-branched NT4 peptide binds heparin, heparan sulfate and chondroitin sulfate with 
different affinity. In order to test its fine specificity, binding of the NT4 branched peptide to different GAGs 
was tested by Biacore. A Biotin-coupled NT4 peptide was captured on a Biacore T100 sensor chip where streptavi-
din had previously been covalently immobilized. Increasing concentrations of heparin, HS, CS or hyaluronic acid 
were then injected on the NT4-coated chip (Fig. 1). No binding of hyaluronic acid was detected. Heparin, HS and 
CS all bound to NT4, though with different affinity. Binding affinity of NT4 to the sulfated GAGs as measured by 
Biacore was higher (0.46 nM) for heparin, and decreased by about one log for HS (3.3 nM) and by another log for 
CS (34 nM). The highest affinity obtained with heparin, whose average number of sulfated groups is higher than 
that of HS and CS12,13, and the absence of binding of hyaluronic acid, which is not sulfated, suggest that sulfated 
groups on the glycan chains contribute to binding affinity of the branched NT4 peptide.
Inhibition of NT4 binding to PANC-1 cancer cells by heparin, HS and CS reflects GAG-NT4 bind-
ing affinity. Since NT4 peptide bound heparin, HS and CS with different affinity, we measured the inhibition 
activity of the three GAGs on NT4 binding to membrane receptors on the human pancreas adenocarcinoma cell 
line PANC-1 by flow cytometry (Fig. 2). Using identical concentrations of heparin, HS and CS, complete inhibi-
tion of NT4 binding was obtained with heparin, about 80% inhibition was obtained with HS and no inhibition 
was detected with the same concentration of CS. This result confirms the specificity of NT4 binding to membrane 
GAGs on cancer cells, with preferential binding to HS.
Binding of NT4 to xylosyltransferase-I-deficient PgsA-745 cell line. The PgsA-745 cell line is 
derived from CHO-K1 cells treated with mutagens and screened for GAG synthesis defective mutants. PgsA-745 
cells have a defect in xylosyltransferase, the enzyme responsible for coupling the first sugar in GAG synthesis, and 
do not produce GAGs.
In order to further verify specific binding to GAGs, we compared NT4 binding to these GAG-defective cells 
and to native CHO-K1 cells by confocal microscopy. As expected, NT4 binding to PgsA-745 cells was much lower 
(Fig. 3), confirming that GAGs are specific NT4 targets on the cell membrane. Nonetheless, flow cytometry anal-
ysis demonstrated that binding of NT4 to PgsA-745 cells, though much lower than to CHO-K1, was still inhibited 
by heparin. Since we had already demonstrated that NT4 binds HSPG as well as endocytic receptors like sortilin, 
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LRP1 and LRP67, the residual binding to PgsA-745 cells might be due to membrane receptors belonging to these 
families. We had already demonstrated that heparin and endocytic receptors compete for NT4 binding.
Inhibition of cancer cell adhesion by NT4. The results of Biacore experiments, confocal microscopy and 
flow cytometry described above indicate that sulfated GAGs are specifically recognized by NT4 on the cancer 
cell membrane. Since sulfated GAGs have an important role in cancer cell adhesion and migration, we tested the 
effect of NT4 on cancer cell adhesion and motility on different supports. Adhesion of PANC-1 human pancreas 
adenocarcinoma cells was tested on cell culture plates coated with human collagen IV, human fibronectin and on 
uncoated plastic wells.
Figure 1. Biacore analysis of NT4-GAGs binding and affinity. (A) Sensorgrams of GAGs (10 μ g/mL) binding 
to surface immobilized NT4. (B–D) Heparin (B), heparan sulfate (C) and chondroitin sulfate (D) binding to 
NT4. Different concentrations of GAGs were injected over biotin-conjugated NT4, previously immobilized on a 
SA sensor chip. (E) Kinetics constants and affinity values of GAGs binding to NT4 peptide.
Figure 2. Flow cytometry of NT4 binding (grey) to PANC-1 cancer cells and inhibition by heparin (oblique 
lines), heparan sulfate (horizontal lines) and chondroitin sulfate (line). 
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Fibronectin exists in different isoforms, obtained by alternative splicing. Soluble plasma fibronectin, which is 
produced by hepatocytes and is abundant in plasma, lacks EDA and EDB domains36, whereas cellular fibronectin 
produced by fibroblasts, epithelial cells and other cell types is a major component of the ECM and contains the 
EDA and/or EDB segments, whose selective expression in cancer tissues has long been known37–39. In view of the 
different roles of plasma and cellular fibronectin, we tested the effect of NT4 peptide on cancer cell adhesion on 
both isoforms of human fibronectin.
NT4 inhibited adhesion of PANC-1 cancer cells to plastic, collagen IV and cellular oncofetal fibronectin with 
overlapping efficiency (EC50 of 2.8e-6 M), whereas adhesion of cancer cells to plasma fibronectin was scarcely 
affected and only at the highest concentration of NT4 (Fig. 4). This result suggests major involvement of HSPGs in 
PANC-1 cancer cell adhesion to cellular fibronectin of the ECM, compared to plasma fibronectin, and a possible 
role of the EDA and/or EDB domain in fibronectin binding to sulfated GAGs.
Inhibition of cancer cell motility by NT4. The effect of NT4 peptide on cancer cell migration was tested 
in vitro in wound healing experiments. PANC-1 cells were grown to confluence on 24-well cell culture plates 
coated with collagen IV, cellular fibronectin or plasma fibronectin and on uncoated wells. A cell-free zone was 
created by inserting a silicone spacer, which was removed once cells had reached confluence. Cells were then 
incubated with different concentrations of NT4 and the void area was monitored. In order to distinguish cell divi-
sion from cell motility, which might both interfere with filling of the void area, the effect of NT4 on cell division 
was checked by MTT assay. NT4 clearly inhibited filling of the cell-free area on uncoated plastic wells as well as 
on plates coated with collagen IV, cellular fibronectin and plasma fibronectin and the effect was dose-dependent 
(Fig. 5). No effect of NT4 peptides on cancer cell division was detected in identical experimental conditions (not 
shown), indicating that the effect on cancer cell re-colonization of the void area was entirely due to inhibition of 
cell migration.
Cancer cell migration was monitored by time lapse microscopy in order to visualize modifications of cancer 
cell morphology or motility produced by the NT4 peptide. Time lapse imaging of cancer cell movements indi-
cated that NT4 does not affect cancer cell morphology or ability to produce protrusions (Fig. 6A, supplementary 
material Figs S1 and S2) but rather the directionality and polarity of cell movement. In wound healing exper-
iments on plates coated with collagen IV, fibronectins or uncoated wells, cancer cells incubated without NT4 
Figure 3. NT4 binding to CHO-K1 and PgsA-745 cells observed by (A) confocal microscopy and (B) flow 
cytometry. (A) CHO-K1 and PgsA-745 cells stained with NT4-biotin, followed by streptavidin-FITC (green). 
Nuclei were stained with DAPI (blue). (B) Inhibition of NT4 binding to CHO-K1 and PgsA-745 cells by 
heparin, analyzed by flow cytometry.
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clearly moved towards the cell-free zone, as indicated by single cell migration tracking (Fig. 7). On the other 
hand, when incubated with NT4, cancer cells seemed to slip on the plate and lose their direction of migration. 
They produced protrusions like in control wells, however these did not produce effective forward migration but 
rather random circular movement with little progression toward the cell-free zone (Figs 6A and 7, supplementary 
material Figs S1 and S2).
NT4 ability to inhibit cell migration of PANC-1 cell was also confirmed in wound healing experiments where 
cells were covered with Matrigel. As expected, in these experiments cell migration and speed were reduced com-
pared to 2D wound healing (supplementary material Figs S3–S5).
The effect of NT4 on cancer cell morphology was also checked by scanning electron microscopy. PANC-1 cells 
were incubated with 10 μ M NT4 for 3 hours and then analyzed (Fig. 6B). No modification of general cell shape or 
cell protrusions was observed.
Inhibition of cancer cell trans-well migration by NT4. In order to evaluate whether NT4 peptide inhib-
ited cancer cell trans-well migration, a classical migration assay on Boyden chambers was performed with PANC-1 
cells (Fig. 8). Cells were incubated for 24 h with different concentration of NT4 (20, 10 and 5 μ M) in uncoated 
or collagen IV-coated upper wells and migrated cells were then counted. Results in Fig. 8 show that 20 μ M 
NT4 caused about 85% and 68% reduction of PANC-1 cells trans-well migration in uncoated and in collagen 
IV-coated Boyden chambers, respectively.
Discussion
In previous papers we reported that NT4 tetra-branched peptides are promising cancer-selective theranostic 
agents by virtue of their ability to selectively deliver different functional units to cancer cells for imaging or ther-
apy. NT4 contains four copies of the human neurotensin sequence, which many years ago had been reported as a 
potential selective cancer-targeting agent because neurotensin receptors seemed to be over-expressed in different 
human cancers. However, we demonstrated that the high cancer selectivity of NT4, not shared by monomeric 
native neurotensin, is actually generated by its multimericity, which switches NT4 selectivity towards membrane 
receptors different from the canonical NTR1 and NTR2 G protein-coupled neurotensin receptors. NT4 was found 
to bind heparin, as well as LRP1, LRP6 and sortilin, by means of a multimeric positively-charged motif that might 
interact with negatively-charged motives in sulfated GAGs and LRP receptors, already known to share several 
different heparin-binding ligands7.
Sulfated GAGs and LRP receptors are over-expressed in different cancer tissues and are involved in sev-
eral aspects of cancer cell differentiation, as well as cancer cell interaction with ECM, cell adhesion and 
migration9,11,14–16,20–25,33–35.
Considering the fundamental role of sulfated GAGs in many aspects of cancer cell biology, we investigated 
NT4 selectivity towards GAGs, as well as the effect produced by NT4 on cancer cell adhesion and migration. 
We found that NT4 binds heparin, HS and CS, which are all sulfated GAGs, but does not bind (non-sulfated) 
hyaluronic acid. Binding affinity of NT4 to sulfated GAGs, as measured by Biacore, was higher for heparin, and 
progressively lower for HS and CS. Inhibition of NT4 binding to human pancreas adenocarcinoma PANC-1 cells 
by the same sulfated GAGs was essentially in line with their binding affinity, with complete inhibition of NT4 
binding obtained with heparin, less inhibition obtained with HS and no inhibition in the presence of the same 
concentration of CS. Since neither binding to NT4 or inhibition of NT4 binding to cancer cell membranes was 
detected with the non-sulfated GAG, hyaluronic acid, and heparin has a greater content of sulfated groups than 
HS and CS12,13,40, the results from affinity and inhibition activity indicate that NT4 specifically binds sulfated 
GAGs on the cancer cell surface, with preferential binding to HS. This result was further confirmed by the very 
low binding of NT4 peptides to the xylosyltransferase-I-deficient PgsA-745 cell line, which does not synthesize 
GAGs. Indeed, binding of NT4 to this GAG-defective cell line was much lower than to the native CHO-K1 cell 
line from which PgsA-745 is derived. Nonetheless, binding of NT4 to PgsA-745 cells, while low, was still com-
pletely inhibited by heparin. This may be explained by NT4 binding to LRP receptors on PgsA-745. Synthesis of 
LRP receptors is not affected by lack of xylosyltransferase I, which is responsible for transfer of the first xylose 
Figure 4. Adhesion assay of PANC-1 cells in the presence of NT4 at different concentrations on plastic, 
collagen IV, cellular fibronectin and plasma fibronectin. Cells were stained with crystal violet and absorbance 
was read at 595 nm. The data is the mean ± SD of two experiments performed in triplicate. P < 0.0001 calculated 
using two-way ANOVA; n (sample size) = 6.
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Figure 5. Wound healing assay. PANC-1 cancer cells were plated on wells coated with collagen IV (A), plasma 
fibronectin (B), cellular fibronectin (C) or on uncoated wells (D) where a silicon spacer had been placed 
immediately before cell plating. Once cells had reached confluence, the silicon spacer was removed and cells 
were treated with different concentrations of NT4 peptide (from 20 μ M to 1 μ M) for 16 hours. (A–D) results 
obtained with 10 μ M NT4. Phase-contrast microscopy images were acquired from each well at time 0 and at the 
end of experiment (16 hours) and analyzed for recording void area, which was reported as percent of void area 
at time 0, for each sample (E). Magnification 5x. * p < 0.05, ** p < 0.01, *** p < 0.001 calculated using one-way 
ANOVA with DUNNETT post-test; n (sample size) = 5.
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residue of any GAG chain to the protein core of HSPG and in fact wild type CHO-K1 and PgsA-745 cells were 
reported to have comparable amount of membrane LRP receptors41. Actually, we previously demonstrated that 
NT4 binds to heparin and LRP receptors via the same multimeric positively-charged motif and that binding to 
endocytic receptors is completely inhibited by heparin7.
Sulfated GAGs and LRP receptors both have an important role in many aspects of cancer cell biology, par-
ticularly aspects related to contact between cancer cells and ECM enabling cell adhesion and migration. We 
then tested the effect of NT4 in adhesion and migration of PANC-1 human pancreas adenocarcinoma cells on 
different ECM proteins. Cell adhesion and migration were tested on non-coated culture plates and plates coated 
with collagen IV or fibronectin. We tested the two main forms of human fibronectin: soluble plasma fibronectin, 
produced by hepatocytes, abundant in plasma, and lacking the EDA and EDB domains, and oncofetal cellular 
fibronectin, which has EDA and/or EDB domains, is produced by fibroblasts, epithelial cells and other cell types 
Figure 6. Cancer cell morphology of PANC-1 in control wells (left panels) and in the presence of 10 μ M 
NT4 peptide (right panels) analyzed by phase contrast light microscopy in wound healing experiments (A) 
(images taken after 3-hour time lapse analysis of cell migration. Magnification 10x) and by scanning electron 
microscopy under static conditions (B). Scale bar 5 µm.
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and is a major component of the ECM. Cancer cell adhesion to uncoated plastic wells, as well as to collagen IV 
and oncofetal fibronectin, was inhibited by NT4 with identical EC50, whereas cell adhesion to plasma fibronectin 
Figure 7. Directionality of cancer cell migration analyzed by time lapse microscopy. PANC-1 cancer cells 
were cultured on collagen IV (A), plasma fibronectin (B), cellular fibronectin (C) and plastic (D), with and 
without 10 μ M NT4 (central panels and left panels, respectively). Cells were tracked every 20 min for 10 hours 
post-wounding and their paths plotted on a polar grid. Each plot represents 15 individual cell tracks. Velocity 
(unit/sec; where unit correspond to nm) of each analysed cell is reported in the box plot graph (right panels) 
where the median value is indicated by the line inside each box. ** p < 0.01, *** p < 0.001 calculated using one-
tailed Student t-test; n (sample size) = 15.
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was almost unaffected by NT4. This confirms that sulfated GAGs are involved in cancer cell adhesion to different 
supports, including oncofetal fibronectin. On the other hand, the lack of inhibition of cancer cell adhesion to 
soluble fibronectin by NT4 suggests that EDA and/or EDB are essential for cell adhesion mediated by sulfated 
GAGs. This is in line with recent data indicating that cellular fibronectin and not plasma fibronectin is involved in 
epithelial mesenchymal transition42, cell adhesion and migration43 in different cancers.
In the wound healing assay, NT4 inhibited cancer cell migration on all supports, including serum and cellu-
lar fibronectin, in contrast to what we observed for cancer cell adhesion, where inhibition by NT4 only affected 
cancer cell adhesion to cellular and not to plasma fibronectin. PANC-1 cancer cell migration was also inhibited 
in wound healing experiments where cells were embedded in Matrigel, although cell migration and speed were 
reduced in this condition compared to the 2D wound healing experiments.
Figure 8. Effect of NT4 on PANC-1 cell trans-well migration in Boyden chambers. PANC-1 cells in the 
presence of different NT4 concentrations (20, 10 and 5 μ M) were seeded on the upper component of trans-well 
inserts of uncoated or collagen IV–coated Boyden chambers and then incubated for 24 h. Migrating cells (A) 
were counted as described in the Methods section. (B) Representative images of migrated cells after 24 h, fixed 
and stained with Crystal violet. ** p < 0.01, *** p < 0.001 calculated using one-way ANOVA with DUNNETT 
post-test; n (sample size) = 10.
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Comparison of cancer cell migration by time lapse analysis, with or without NT4, showed that inhibition of 
cell migration was not accompanied by any dramatic modification of cell morphology and NT4 did not affect cell 
ability to produce protrusions. Moreover, NT4 did not modify cell morphology even under static conditions, as 
verified by scanning electron microscopy of cells incubated with NT4. What appeared to be dramatically affected 
by NT4 was cell ability to move towards the void space by oriented migration. In the presence of NT4, cancer cells 
lost their direction of migration and their average speed was therefore significantly reduced. This was evident in 
wound healing experiments in uncoated wells, as well as on plates coated with collagen, with either cellular or 
plasma fibronectin, as well as in Matrigel. Moreover NT4 dramatically reduced cancer cell migration in trans-well 
experiments.
These results suggest that although sulfated GAGs appear to be crucial for cancer cell adhesion and migration, 
different mechanisms of cancer cell contact with ECM proteins, particularly with fibronectin, seem to be involved 
in cell migration in contrast with the static conditions of cancer cell adhesion experiments. Our results indicate 
that fibronectin EDA and/or EDB domains could be determinant for interaction with sulfated GAGs for cancer 
cell adhesion under static conditions, but not for cancer cell migration.
A fundamental role of HSPGs has already been reported in endothelial cell migration and mechanotransduc-
tion, where, in addition to regulating cell adhesion and migration speed, HSPGs seem to be important in sensing 
the direction of shear stress and transmitting the mechanical signal into the intracellular space. This signaling 
might be able to regulate the direction of cell migration44. Interestingly, in the same paper a different role of HSPG 
in cancer cell adhesion and migration was reported, which is in line with our results. Moreover, a monoclonal 
antibody targeting the HS chain of glypican 3 was recently reported to inhibit migration of hepatocellular carci-
noma cells45.
Since NT4 peptides bind to sulfated GAGs and also to LRP receptors via the same multimeric ligand motif, we 
cannot distinguish which of the two receptor families is more involved in the effect produced by NT4 in cancer 
cell adhesion and migration. Nonetheless, results obtained with the GAG defective PgsA-745 cell line strongly 
suggest that the effect of NT4 on cancer cell migration is mostly related to its interference with the function of 
sulfated GAGs. Although it has long been recognized that HSPG are crucial for cell adhesion and migration, 
their role in respect of the better characterized function of integrins has not been fully characterized. HSPG were 
assigned a sort of supporting role in the organization of cell contacts with ECM and were generally considered as 
integrin co-receptors. In the last few years results were reported suggesting that beside the integrin-ECM contacts 
and related intracellular responses, HSPG are essential for the correct organization of focal adhesion, stress fibers 
and intracellular signaling leading to oriented cell migration46–48.
By using a selective ligand of HSPG sulfated GAG chains, we have here provided strong indications of a pri-
mary role of HSPG in cell adhesion and migration. Moreover, our results confirm the hypothesis of a synergic role 
of HSPG and LRP receptors, which besides sharing many morphogenic ligands and collaborating in modulating 
their cell signals, may also share binding sites on different ECM macromolecules and therefore collaborate in 
maintaining and modulating contacts and relationships between cancer cells and ECM, as well as in controlling 
the directionality of cancer cell migration. In conclusion, our results suggest that besides their possible use as 
selective cancer theranostics, NT4 peptides may interfere with cancer cell migration and adhesion, thus reducing 
tumor aggressiveness and metastatic potential. The results also provide insights into the role of HSPG and LRP 
receptors in cancer cell motility and adhesion to different ECM proteins.
Experimental Procedures
Peptide Synthesis. Peptides were synthesized on an automated multiple synthesizer (MultiSynTech, 
Germany) by standard Fmoc chemistry. Protected L-amino acids, Tentagel-resin and Fmoc4-Lys2-
Lys-beta-Ala-Wang resin were purchased from Iris Biotech, Germany, the coupling reagent DIPEA 
(N,N-diisopropylethylamine) from Merck and HBTU (O-benzotriazole-N,N,N′ ,N′ -tetramethyl-uronium-hex-
afluoro-phosphate) from MultiSynTech and DIPEA (N,N-diisopropylethylamine) from Merck. Tetra-branched 
peptides were synthesized either on Fmoc4-Lys2-Lys-beta-Ala-Wang resin or built using two consecutive 
Fmoc-Lys(Fmoc)-OH coupling steps to form the branched core on Tentagel-resin. NT4-biotin was synthesized 
on Tentagel resin with Fmoc-Lys(biotin)-OH as first coupling step, and Fmoc-PEG12-OH as second; Fmoc-
Lys(Fmoc)-OH was then used to build the tetrameric core. Pyro-Glu-O-pentachlorophenylester (Bachem, 
Switzerland) was used for the last coupling step, since pyro-Glu is the N-terminal acid of the neurotensin 
sequence. Peptides were finally cleaved from the resin, deprotected and lyophilized.
HPLC purification was performed on a C18 Jupiter column (Phenomenex). Water with 0.1% TFA (A) 
and methanol (B) were used as eluents. Linear gradients over 30 min were run at flow rates of 0.8 ml/min and 
4 ml/min for analytical and preparatory procedures, respectively. All compounds were also characterized on a 
BrukerUltraflex MALDI TOF/TOF Mass Spectrometer.
NT4 (pyELYENKPRRPYIL)4K2K-beta-Ala MS: m/z calculated for C333H519N91O81 [M+ H]+ : 7094.24. 
Found 7095.15. HPLC RT (from 80%A to 20%A) 26.63 min. Biotinylated NT4 (pyELYENKPRRPYIL)4K2K- 
PEG12- K(biotin)MS: m/z calculated for C373H594N96O95S [M+ H]+ : 7976.35. Found 7978.72. HPLC RT 
(from 80%A to 20%A) 26.99 min.
SPR experiments. Experiments were performed on a Biacore T100 instrument (GE Healthcare). All mate-
rials were purchased from GE Healthcare unless otherwise specified.
NT4-biotin immobilization. NT4 biotin was captured on a CM5 sensor chip previously immobilized with 
streptavidin through standard amine coupling. Briefly, the sensor chip surface was activated with a mixture 
of 0.1 M 1-ethyl-3(3-dimetylaminopropyl)-carbodimide (EDC) and 0.4 M N-hydroxyl succinimide (NHS) 
for 7 minutes at a flow rate of 5 μ l/min. Streptavidin was injected over the surface for 7 minutes and finally 1 M 
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ethanolamine pH 8.5 was used to block any activated carboxyl groups. NT4 peptide conjugated with biotin, 
diluted in HBS-EP+ (Hepes 10 mM, NaCl 150 mM, 3.4 mM EDTA, 0.05% p20, pH7.4) at 30 μ g/ml, was injected 
for 2 min at a flow rate of 10 μ l/min.
GAGs kinetics. GAGs were diluted at concentrations ranging in HBS-EP+ and then injected over immobilized 
NT4 peptides. The sensor chip surface was regenerated with a short pulse of 10 mM NaOH / 0.5 M NaCl 5 minutes 
after the end of the injections.
Kinetics were analyzed with “Biacore T100 evaluation 1.1.1” software using the Langmuir model 1:1 for fitting 
curves.
Cell lines. PANC-1 human pancreas adenocarcinoma, CHO-K1 Chinese hamster ovary cell and 
PgsA-745 Chinese hamster ovary cell mutant deficient in xylosyltransferase (UDP-D-xylose: serine- 
1,3-D-xylosyltransferase) were grown in DMEM Medium (for PANC-1 and CHO-K1) and F 12 K Medium sup-
plemented with 10% fetal bovine serum, 200 μ g/ml glutamine, 100 μ g/ml streptomycin and 60 μ g/ml penicillin. 
Cell lines were purchased from ATCC (The Global Bioresource Center).
Flow cytometry. All experiments were performed using 1 × 105 PANC-1, CHO-K1 or PgsA-745 cells in 
96-well U-bottom plates. For peptide binding, cells were incubated with 1 μ M NT4-biotin for 30 min at room 
temperature; inhibition of NT4 binding by GAGs was carried out incubating cells with 1 μ M biotinylated NT4 and 
100 μ g/ml GAGs. Cells were finally incubated with 1 μ g/ml Streptavidin-FITC. All dilutions were performed in 
PBS, containing 5 mM EDTA and 0.5% BSA.
10000 events were analyzed in a BD FACS Calibur (Becton Dickinson, NJ USA). Results were analyzed by FCS 
Express 4 Plus software.
Confocal Microscopy. PgsA-745 and CHO-K1 cells were plated at a density of 3 × 104 per well in 24-well 
plates with cover glass slides. Samples were fixed through incubation with a PBS- (137 mM NaCl, 2 mM KCl, 
10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4, PBS) 4% paraformaldehyde (PFA) solution for 15 min, saturated for 
30 min at 37 °C with PBS-1% bovine serum albumin (BSA) and incubated with 1 μ M biotinylated peptides for 
30 min at room temperature, then with 0.5 μ g/ml Streptavidin-FITC for 15 min at room temperature. Samples, 
mounted using Fluoroshield with DAPI (Sigma Aldrich), were analyzed by confocal laser microscope (Leica TCS 
SP5) with 364–488 nm excitation and 458–519 nm emission filters for DAPI and FITC, respectively. All images 
were processed using ImageJ software (NIH).
Cancer cell adhesion. 96-well plates were coated with 20 μ g/ml human collagen IV and with 10 μ g/ml 
human cellular fibronectin and human plasma fibronectin (Sigma Aldrich) for 2 h at 37 °C and then washed three 
times with PBS. PANC-1 cells were plated at a concentration of 1 × 105 cells/well in a 96-well plate for 30 minutes 
at 37 °C with different concentrations of NT4 (from 1 μ M to 10 μ M). Cells were then fixed with PBS - 4% PFA 
for 15 minutes at room temperature and stained with 0.1% crystal violet in 200 mM MES (2-(N-morpholino)
ethanesulfonic acid) pH 6.0 for 1 h at room temperature. The cells were then solubilized with 10% acetic acid 
and the absorbance was measured at 595 nm using a microplate reader. The experiment was performed twice in 
triplicate.
EC50 values were calculated by non-linear regression analysis using Graph Pad Prism 5.03 software.
Wound healing. Cell migration was measured using an in vitro wound healing assay. Briefly, PANC-1 cells 
(2 × 105 cells/well) were seeded on each side of a culture insert for live cell analysis (Ibidi, Munich, Germany). 
Inserts were placed in wells of a pre-coated 24-well plate (20 μ g/ml human collagen IV and 10 μ g/ml human cel-
lular fibronectin and human plasma fibronectin (Sigma Aldrich) for 2 h at 37 °C) and incubated at 37 °C and 5% 
CO2 to allow cells grow to confluence. Afterwards, inserts were removed with sterile tweezers to create a cell-free 
area of approximately 500 μ m and cells were treated with NT4 peptide at different concentrations (20, 10, 5 and 
1 μ M) in complete medium. Cells were allowed to migrate in an appropriate incubator.
CytoSMART Lux 10x System (Lonza) was used to take a picture at time point zero and every 10 min for a total 
of 22 h. At the beginning and end of the time intervals the wound area was visualized under an inverted micro-
scope (Zeiss Axiovert 200 microscopy) at 5x magnification and photographed with a Nikon ACT-1 Version 2.63 
camera. The percentage of void area with respect to time 0 was determined using Tscratch software after 16 h, 
when control wells had completely filled the gap.
The time lapse stacks of images were also analyzed using ImageJ and the two plug-ins: Manual Tracking, and 
Chemotaxis and Migration Tool. Individual cells were randomly selected and tracked throughout the 10 h time 
period.
Scanning electron microscopy. The morphology of cancer cells was investigated by Scanning Electron 
Microscopy (SEM). PANC-1 cells were plated at a density of 3 × 104 per well in 24-well plates with cover glass 
slides and incubated with 10 μ M NT4 peptide in complete medium for 3 h at 37 °C. Cells were fixed in 2.5% glu-
taraldehyde solution in phosphate buffer 0.1 M pH 7.2 (PB) for 2 h at 4 °C, washed in PB, postfixed in 1% OsO4 
in PB for 30 min at 4 °C, dehydrated in ascending alcohol series, incubated for 10 min in tert-butanol, and finally 
freeze dried.
Afterwards, the coverslip was mounted on an aluminum stub, coated with 20 nm gold in a Balzers MED010 
sputtering device, and observed in a Philips XL20 scanning electron microscope operating at an electron accel-
erating voltage of 10 kV.
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Trans-well cell migration. Standard trans-well inserts for 24-well plates (transparent PET membrane, 8.0 μ 
m pore size, Corning) were equilibrated with serum free tissue culture medium for 2 h at 37 °C. In a set of exper-
iment the upper compartment was coated with 20 μ g/ml of human collagen IV. 35000 PANC-1 cells diluted in 
serum free medium containing NT4 (20, 10 or 5 μ M), were placed in uncoated or collagen IV-coated upper 
chambers and the lower chambers were filled with medium containing 10% serum. After 24 h incubation at 37 °C 
in a humidified atmosphere with 5% CO2, cells were fixed with 4% PFA in PBS and stained with Crystal Violet. 
Non-invading cells were then removed from the top of the membrane using a cotton swab dipped in PBS, accord-
ing to the manufacturer’s protocol. Ten field images for each Boyden chamber were taken with a 10x objective in 
a Zeiss Axiovert 200 microscope. Cells were counted using the ImageJ software, NIH.
Cancer cell migration in Matrigel. Cell migration was measured using an in vitro wound healing assay in 
the presence of Matrigel (Corning Matrigel Basement membrane Matrix). Briefly, PANC-1 cells (2 × 105 cells/well) 
were seeded on each side of a culture insert for live cell analysis (Ibidi, Munich, Germany). Inserts were placed 
in 24-well plate and incubated at 37 °C and 5% CO2 to allow cells grow to confluence. Inserts were removed with 
sterile tweezers to create a cell-free area of approximately 500 μ m. Wells were covered with Matrigel for 30 min at 
37 °C and then 10 μ M of NT4 peptide in complete medium was added to each well. Cells were allowed to migrate 
in an appropriate incubator. CytoSMART Lux 10x System (Lonza) was used to take a picture at time point zero 
and every 7.5 min for a total of 42 h.
Statistical analysis. All our data are parametric data calculated with Kolmogorov-Smirnov (KS) test using 
Graph Pad Prism 5.0 software.
P values were calculated using: two-way ANOVA for adhesion assay (Fig. 4), one-way ANOVA with Dunnett 
post-test for wound healing assay (Fig. 5E) and for invasion assay (Fig. 8) and one-tailed Student’s t-test for direc-
tionality of cancer cell migration analyzed by time lapse microscopy (Fig. 7) using Graph Pad Prism 5.03 software. 
All p values were reported in figure legends.
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